Literature DB >> 2179900

Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass.

A N Kong1, G L Jungbluth, M T Pasko, T R Beam, W J Jusko.   

Abstract

The pharmacokinetics of methylprednisolone sodium succinate (MPHS) and methylprednisolone (MP) were determined in six patients undergoing open heart surgery with cardiopulmonary bypass. Plasma concentrations of both compounds were measured by high-performance liquid chromatography after doses of MPHS of 1.7-2.4 g. The prodrug ester MPHS yields MP with an average formation rate constant of 0.70 +/- 0.29 hr-1. Peak concentrations of MP occur around 1-2 hours after loading and additional administration of MPHS. The pharmacokinetic values of the two drugs in patients having cardiopulmonary bypass were compared to those in younger, healthy subjects. The volume of distribution of MPHS was lower in the patients, and that of MP was similar to the value in controls. Total clearances of both agents were reduced by about 5 and 2 times. The elimination half-life of MPHS was increased slightly, whereas that of MP increased more than twice in the patients. Significant alterations in clearances occurred in patients, but concentrations of MP were appreciable and prolonged MP due to the extensive formation of MP from MPHS and reduced clearance of MP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2179900

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  7 in total

1.  Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats.

Authors:  Anasuya Hazra; Nancy A Pyszczynski; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Pharm Res       Date:  2007-08-03       Impact factor: 4.200

2.  Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids.

Authors:  Anasuya Hazra; Nancy Pyszczynski; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-06-26       Impact factor: 2.745

3.  Methylprednisolone-hemisuccinate and its metabolites in serum, urine and bile from two patients with acute graft rejection.

Authors:  G J Lawson; J Chakraborty; J M Tredger; E M Baylis
Journal:  Br J Clin Pharmacol       Date:  1995-02       Impact factor: 4.335

4.  Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass.

Authors:  Christoph P Hornik; Daniel Gonzalez; Julie Dumond; Huali Wu; Eric M Graham; Kevin D Hill; Michael Cohen-Wolkowiez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-10-23

5.  Factors associated with hyperglycemia and low insulin levels in children undergoing cardiac surgery with cardiopulmonary bypass who received a single high dose of methylprednisolone.

Authors:  Ronaldo Arkader; Luiz Marcelo Malbouisson; Gilda Maria Barbaro Del Negro; Lidia Yamamoto; Thelma Suely Okay
Journal:  Clinics (Sao Paulo)       Date:  2013-01       Impact factor: 2.365

6.  Comparison between preoperative administration of methylprednisolone with its administration before and during congenital heart surgery on serum levels of IL-6 and IL-10.

Authors:  Mohammad Abbasi Tashnizi; Ghasem Soltani; Ali Asghar Moeinipour; Hossein Ayatollahi; Amir Saber Tanha; Lida Jarahi; Alireza Sepehri Shamloo; Nahid Zirak
Journal:  Iran Red Crescent Med J       Date:  2013-02-05       Impact factor: 0.611

7.  Comparing the effect of preoperative administration of methylprednisolone and its administration before and during surgery on the clinical outcome in pediatric open heart surgeries.

Authors:  Ghasem Soltani; Mohammad Abbasi Tashnizi; Ali Asghar Moeinipour; Mahmoud Ganjifard; Jamil Esfahanizadeh; Alireza Sepehri Shamloo; Seyed Javad Purafzali Firuzabadi; Nahid Zirak
Journal:  Iran Red Crescent Med J       Date:  2013-06-05       Impact factor: 0.611

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.